PCM
SRNE

Prelude Capital Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Prelude Capital Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,300
Closed -$39.4K – 2511
2020
Q2 		$27K Buy
+4,300
New +$16.5K ﹤0.01% 1328
2018
Q2 		– Sell
-9,695
Closed -$50K – 2031
2018
Q1 		$50K Hold
9,695
– – ﹤0.01% 1080
2017
Q4 		$37K Buy
+9,695
New +$25.3K ﹤0.01% 1004

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Prelude Capital Management's SRNE Position: Q3 2020 in Review

Prelude Capital Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2020, closing a stake of 4,300 shares — an estimated $39.4K sold.

Prelude Capital Management first reported a position in SRNE in Q4 2017 and held it in 3 quarters. The position peaked at $50K in Q1 2018. 209 funds tracked by Wall St. Rank hold SRNE as of Q3 2020.

  • Prelude Capital Management reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2020 after selling out during the quarter.
  • Prelude Capital Management sold 4,300 Sorrento Therapeutics, Inc. shares in Q3 2020, an estimated $39.4K.
  • Prelude Capital Management first reported a position in Sorrento Therapeutics, Inc. in Q4 2017 and held it in 3 quarters.
  • Prelude Capital Management's Sorrento Therapeutics, Inc. position peaked at $50K in Q1 2018.
  • 209 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2020.

Based on Prelude Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.